Tower Research Capital LLC (Trc) Cognition Therapeutics Inc Transaction History

Tower Research Capital LLC (Trc)

  • $3.29 Billion
  • Q1 2025

A detailed history of Tower Research Capital LLC (Trc) transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,444 shares of CGTX stock, worth $782. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,444
Previous 20,970 88.35%
Holding current value
$782
Previous $15,000 93.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025
SELL
$0.39 - $0.85 $7,225 - $15,747
-18,526 Reduced 88.35%
2,444 $1,000
Q4 2024

Feb 13, 2025
BUY
$0.38 - $0.84 $3,792 - $8,383
9,980 Added 90.81%
20,970 $15,000
Q3 2024

Nov 14, 2024
BUY
$0.41 - $2.37 $147 - $850
359 Added 3.38%
10,990 $5,000
Q2 2024

Aug 13, 2024
BUY
$1.66 - $2.62 $6,993 - $11,038
4,213 Added 65.64%
10,631 $17,000
Q1 2024

May 15, 2024
BUY
$1.78 - $2.53 $2,760 - $3,924
1,551 Added 31.87%
6,418 $11,000
Q4 2023

Feb 13, 2024
BUY
$0.96 - $2.42 $1,255 - $3,165
1,308 Added 36.75%
4,867 $9,000
Q3 2023

Nov 14, 2023
SELL
$1.25 - $1.9 $878 - $1,335
-703 Reduced 16.49%
3,559 $5,000
Q2 2023

Aug 14, 2023
SELL
$1.56 - $3.38 $1,658 - $3,592
-1,063 Reduced 19.96%
4,262 $7,000
Q1 2023

May 09, 2023
BUY
$1.51 - $2.3 $1,707 - $2,601
1,131 Added 26.97%
5,325 $11,000
Q4 2022

Feb 10, 2023
BUY
$1.17 - $3.51 $3,810 - $11,432
3,257 Added 347.6%
4,194 $9,000
Q3 2022

Nov 10, 2022
SELL
$1.63 - $3.6 $1,581 - $3,492
-970 Reduced 50.87%
937 $2,000
Q2 2022

Aug 15, 2022
BUY
$1.5 - $3.45 $2,860 - $6,579
1,907 New
1,907 $4,000

Others Institutions Holding CGTX

# of Institutions
58
Shares Held
14M
Call Options Held
0
Put Options Held
0
View Full List

About COGNITION THERAPEUTICS INC

CGTX Quotes by TradingView
  • Ticker CGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,710,700
  • Market Cap $7.27M
  • Description
  • Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...
More about CGTX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email